Abstract:Introduction: Though largely preventable, cervical cancer remains a significant health issue. Treatment of early-stage disease usually involves surgery; while systemic therapy is often required for advanced, recurrent, or metastatic cases. Most patients with advanced disease receive cisplatin-containing chemotherapy combinations in the first-line setting. TTFields are electric fields that disrupt cellular processes critical for cancer cell viability and tumor progression. Concomitant treatment with TTFields and cisplatin has shown benefit in other tumor types. This in vitro study assessed the effects of TTFields in cervical cancer cells and explored their efficacy together with cisplatin. Methods: Cervical cancer cell lines were exposed to TTFields (0.5 V/cm for Ca Ski cells, 1 V/cm RMS for HeLa and SiHa cells; 72 h) at varying frequencies (100-400 kHz) followed by cell count assays. TTFields (200 kHz) were then applied with a range of cisplatin doses, and cell count, colony formation, and apoptosis were evaluated. Overall effect was calculated as the product of the relative reductions in cell count and colony formation. TTFields-treated cells were also examined for formation of γH2AX (a DNA damage marker) using fluorescent microscopy and for the expression of Fanconi Anemia (FA)-BRCA pathway proteins involved in repairing cisplatin-induced DNA damage via Western blot. Results: TTFields treatment reduced cell count in all cervical cancer cell lines tested. A frequency of 200 kHz was determined effective and used for all experiments. Cisplatin exhibited dose-response effects, which were augmented when TTFields were co-applied. TTFields also induced DNA damage in the cells and downregulated the expression of FA-BRCA pathway proteins. Conclusions: These preclinical findings suggest that TTFields should be explored as a potential treatment for cervical cancer. TTFields-induced downregulation of the FA-BRCA pathway creates a conditional vulnerability that may account for the enhanced efficacy seen when TTFields are applied together with cisplatin, providing mechanistic insight. Citation Format: Roni Frechtel-Gerzi, Daria Gerasimova, Einav Zeevi, Roni Monin, Hila Fishman, Inbar Schlachet-Drukerman, Helena Mumblat, Antonia Martinez-Conde, Eyal Dor-On, Itai Tzchori, Adi Haber, Moshe Giladi, Uri Weinberg, Yoram Palti, Greg Palmer, Angeles A. Secord. Preclinical effects of Tumor Treating Fields (TTFields) applied with cisplatin for treatment of cervical cancer [abstract]. In: Proceedings of the AACR Special Conference in Cancer Research: DNA Damage Repair: From Basic Science to Future Clinical Application; 2024 Jan 9-11; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2024;84(1 Suppl) nr B028.

Abstract B028: Preclinical effects of Tumor Treating Fields (TTFields) applied with cisplatin for treatment of cervical cancer